Evidence map›Paper›PMID 36510222›Full record

Trial reportJournal of translational medicine2022

Longitudinal transcriptional analysis of peripheral blood leukocytes in COVID-19 convalescent donors.

Mallikarjuna R Gedda, Patrick Danaher, Lipei Shao, Martin Ongkeko, Leonard Chen, Anh Dinh, Mame Thioye Sall, Opal L Reddy, Christina Bailey, Amy Wahba and 7 more

Registry-linked trialOpen access · goldAbstract readClinical Trial
In one paragraph

Trial report in Journal of translational medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04360278 (Plasma Collection From Convalescent and/or Immunized Donors for the Treatment of COVID-19), which is not on this map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
2.2field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04360278 completednot on this map

Plasma Collection From Convalescent and/or Immunized Donors for the Treatment of COVID-19

TypeobservationalSponsorNational Institutes of Health Clinical Center (CC)Ran2020 to 2022Enrolled258ConditionsCOVID-19
3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 18 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 2 institutions in 1 country.

Mallikarjuna R Gedda *Center for Cellular Engineering, Department of Transfusion Medicine, National Institutes of Health, Bethesda, MD, 20892, USA.
Patrick Danaher *NanoString Technologies, Seattle, WA, 98109, USA.
Lipei ShaoCenter for Cellular Engineering, Department of Transfusion Medicine, National Institutes of Health, Bethesda, MD, 20892, USA.
Martin OngkekoCenter for Cellular Engineering, Department of Transfusion Medicine, National Institutes of Health, Bethesda, MD, 20892, USA.
Leonard ChenBlood Services Section, Department of Transfusion Medicine, National Institutes of Health, Bethesda, MD, 20892, USA.
Anh DinhCenter for Cellular Engineering, Department of Transfusion Medicine, National Institutes of Health, Bethesda, MD, 20892, USA.
Mame Thioye SallCenter for Cellular Engineering, Department of Transfusion Medicine, National Institutes of Health, Bethesda, MD, 20892, USA.
Opal L ReddyCenter for Cellular Engineering, Department of Transfusion Medicine, National Institutes of Health, Bethesda, MD, 20892, USA.
Christina BaileyNanoString Technologies, Seattle, WA, 98109, USA.
Amy WahbaNanoString Technologies, Seattle, WA, 98109, USA.
Inna DzekunovaNanoString Technologies, Seattle, WA, 98109, USA.
Robert SomervilleCenter for Cellular Engineering, Department of Transfusion Medicine, National Institutes of Health, Bethesda, MD, 20892, USA.
Valeria De GiorgiInfectious Disease Section, Department of Transfusion Medicine, National Institutes of Health, Bethesda, MD, 20892, USA.
Ping JinCenter for Cellular Engineering, Department of Transfusion Medicine, National Institutes of Health, Bethesda, MD, 20892, USA.
Kamille WestBlood Services Section, Department of Transfusion Medicine, National Institutes of Health, Bethesda, MD, 20892, USA.
Sandhya R PanchCenter for Cellular Engineering, Department of Transfusion Medicine, National Institutes of Health, Bethesda, MD, 20892, USA. srpanch@uw.edu.
David F StroncekCenter for Cellular Engineering, Department of Transfusion Medicine, National Institutes of Health, Bethesda, MD, 20892, USA. dstroncek@cc.nih.gov.ORCID 0000-0001-5867-3265
National Institutes of Health · USNanostring Technologies (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundSARS-CoV2 can induce a strong host immune response. Many studies have evaluated antibody response following SARS-CoV2 infections. This study investigated the immune response and T cell receptor diversity in people who had recovered from SARS-CoV2 infection (COVID-19).

methodsUsing the nCounter platform, we compared transcriptomic profiles of 162 COVID-19 convalescent donors (CCD) and 40 healthy donors (HD). 69 of the 162 CCDs had two or more time points sampled.

resultsAfter eliminating the effects of demographic factors, we found extensive differential gene expression up to 241 days into the convalescent period. The differentially expressed genes were involved in several pathways, including virus-host interaction, interleukin and JAK-STAT signaling, T-cell co-stimulation, and immune exhaustion. A subset of 21 CCD samples was found to be highly "perturbed," characterized by overexpression of PLAU, IL1B, NFKB1, PLEK, LCP2, IRF3, MTOR, IL18BP, RACK1, TGFB1, and others. In addition, one of the clusters, P1 (n = 8) CCD samples, showed enhanced TCR diversity in 7 VJ pairs (TRAV9.1_TCRVA_014.1, TRBV6.8_TCRVB_016.1, TRAV7_TCRVA_008.1, TRGV9_ENST00000444775.1, TRAV18_TCRVA_026.1, TRGV4_ENST00000390345.1, TRAV11_TCRVA_017.1). Multiplexed cytokine analysis revealed anomalies in SCF, SCGF-b, and MCP-1 expression in this subset.

conclusionsPersistent alterations in inflammatory pathways and T-cell activation/exhaustion markers for months after active infection may help shed light on the pathophysiology of a prolonged post-viral syndrome observed following recovery from COVID-19 infection. Future studies may inform the ability to identify druggable targets involving these pathways to mitigate the long-term effects of COVID-19 infection.

trial registrationhttps://clinicaltrials.gov/ct2/show/NCT04360278 Registered April 24, 2020.

Indexed as

COVID-19Antibodies, ViralCytokinesHumansImmunization, PassiveRNA, ViralSARS-CoV-2Antibodies, ViralCytokinesRNA, ViralCOVID convalescent donorsCytokinesImmune exhaustionImmune responseInflammationSARS-CoV2Transcriptome

Identifiers

PMID36510222
PMCPMC9742656
OpenAlexW4312067618

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.